Horizon Kinetics Medical ETF

MEDX
ETF Ticker

+6.30%

+12.15%

NASDAQ

Equity

United States

Sector

The Horizon Kinetics Medical ETF, MEDX_US, is an actively managed strategy providing exposure to United States, Sector Equity. It is listed on the NASDAQ and has assets under management of $17.2m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Jan 27, 2023. It has a net expense ratio of 85bps. (All data in USD as of Oct 9, 2026 unless stated.)

The investment strategy guiding the actively managed Horizon Kinetics Medical ETF seeks long term capital growth by investing, under normal conditions, at least 80% of net assets in equity securities of U.S. and foreign companies engaged in medical research, pharmaceuticals and medical technology, with an emphasis on oncology drug discovery. Eligible issuers generally derive ≥50% of revenue from these activities. Security selection applies fundamental analysis emphasizing research and development intensity alongside balance sheet strength, revenues, earnings and dividends. The portfolio may own companies of any size and may concentrate its exposure, is non diversified, and can exceed 25% in targeted medical industries. The strategy may purchase and write options for hedging or direct exposure, invest up to 20% in below investment grade debt, hold significant cash defensively, invest in other ETFs, and lend portfolio securities. Positions are trimmed or sold upon valuation realization or adverse business developments.

ETF Details

Key Facts

Issuer:
Horizon Kinetics
AUM:
$17.2m (as of Aug 31, 2026)
Net Expense Ratio:
85 bps
Inception Date:
Jan 27, 2023
Index:
Actively managed strategy
Dividend Frequency:
Distributing

Trading

Ticker:
MEDX
Exchange:
NASDAQ
ISIN:
US53656G5633
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
United States
Theme:
Sector
Economic Development:
Developed Markets
1 Year Volatility:
18.79%
3 Year Volatility:
18.14%
5 Year Volatility:
N/A

Performance

TTM Dividend Yield:
1.28% (verify with issuer)
1 Month Performance:
0.15%
3 Month Performance:
-2.97%
6 Month Performance:
4.80%
1 Year Performance:
12.15%
3 Year Performance:
31.25%
5 Year Performance:
N/A
Investment Proposition

Horizon Kinetics Medical ETF (MEDX) presents targeted exposure to companies behind patented, first-line pharmaceuticals and biologics, focusing on businesses with durable intellectual property, high entry barriers and the potential for long product cycles. The actively managed strategy seeks long-term capital growth by concentrating on firms where innovation, pricing power and clinical relevance can translate into attractive unit economics over time, while maintaining a patient, research-driven approach to intrinsic value realization. Portfolio turnover is expected to reflect multi-year theses rather than rapid trading, though the fund may adjust for pipeline readouts or competitive shifts. Key characteristics include meaningful industry and idiosyncratic risk, binary outcomes around trial or regulatory events, and sensitivity to policy environments and reimbursement dynamics; factor exposures may tilt toward quality and profitability with episodic growth traits. In portfolios, it can serve as a satellite for thematic mandates, a source of potential portfolio alpha, or a targeted growth sleeve. Suitable investors include research-oriented allocators and total-return strategies seeking concentrated exposure to medical innovation. Regimes with improving risk appetite and supportive funding conditions often help; broad risk-off phases can challenge. Monitor concentration and clinical/regulatory event risk as a persistent, fund-specific consideration.

ETF Analytics

Fund Discovery

4 Suggestions